Plasminogen activator inhibitor 1 (PAI-1) is the primary physiological inhibitor of plasminogen activation in vivo, and thus it is one of the main regulators of the fibrinolytic system. In this regard, individuals with elevated PAI-1 seem to have an increased risk for thrombotic disease, whereas those lacking the inhibitor develop a lifelong bleeding diathesis. Unexpectedly, recent observations demonstrate that cancer patients with high PAI-1 levels have a poor prognosis for survival. This correlation with metastatic disease may be related to the observation that high PAI-1 levels decrease the adhesive strength of cells for their substratum, and that this de-adhesive activity of PAI-1 is not related to its role as a protease inhibitor. Initial insights into potential mechanisms by which PAI-1 regulates the attachment, detachment, and migration of cells are addressed in this review.
HekmanCM, LoskutoffDJ. Fibrinolytic pathways and the endothelium. Semin Thromb Hemost13: 514527, 1987.
2.
AndreasenPA, EgelundR, PetersenHH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci57: 2540, 2000.
3.
StricklandS. Tissue plasminogen activator in nervous system function and dysfunction. Thromb Haemost86: 138143, 2001.
4.
MondinoA, ResnatiM, BlasiF. Structure and function of the urokinase receptor. Thromb Haemost82(Suppl 1): 1922, 1999.
5.
PlougM. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharmaceut Design9: 14991528, 2003.
6.
SideniusN, BlasiF. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev22: 205222, 2003.
EricksonLA, HekmanCM, LoskutoffDJ. The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci USA82: 87108714, 1985.
11.
BoothNA, SimpsonAJ, CrollA, BennettB, MacgregorIR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol70: 327333, 1988.
12.
DeclerckPJ, De MolM, AlessiM-C, BaudnerS, PaquesE-P, PreissnerK, Müller-BerghausG, CollenD. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem263: 1545415461, 1988.
13.
MimuroJ, LoskutoffDJ. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix: evidence that the protein is vitronectin. J Biol Chem264: 936939, 1989.
14.
FoekensJA, PetersHA, LookMP, PortengenH, SchmittM, KramerMD, BrunnerN, JanickeF, Meijer-van GelderME, Henzen-LogmansSC, van PuttenWL, KlijnJG. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res60: 636643, 2000.
15.
DengG, CurridenSA, WangS, RosenbergS, LoskutoffDJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?J Cell Biol134: 15631571, 1996.
16.
DengG, CurridenSA, HuG, CzekayR-P, LoskutoffDJ. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol189: 2333, 2001.
17.
StefanssonS, LawrenceDA. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin. Nature383: 441443, 1996.
18.
DegryseB, NeelsJG, CzekayR-P, AertgeertsK, KamikuboY, LoskutoffDJ. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem279: 2259522604, 2004.
19.
CzekayR-P, AertgeertsK, CurridenSA, LoskutoffDJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol160: 781791, 2003.
20.
SeiffertD, CiambroneG, WagnerNV, BinderBB, LoskutoffDJ. The somatomedin B domain of vitronectin: structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem269: 26592666, 1994.
21.
MimuroJ, LoskutoffDJ. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J Biol Chem264: 50585063, 1989.
22.
van MeijerM, PannekoekH. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis9: 263276, 1995.
23.
WeiY, WaltzDA, RaoN, DrummondRJ, RosenbergS, ChapmanHA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem269: 3238032388, 1994.
24.
OkumuraY, KamikuboY, CurridenSA, WangJ, KiwadaT, FutakiS, KitagawaK, LoskutoffDJ. Kinetic analysis of the interaction between vitronectin and the urokinase receptor. J Biol Chem277: 93959404, 2002.
25.
WeiY, EbleJA, WangZ, KreidbergJA, ChapmanHA. Urokinase receptors promote β1 integrin function through interactions with integrin α3β1. Mol Biol Cell12: 29752986, 2001.
26.
TaruiT, MazarAP, CinesDB, TakadaY. Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem276: 39833990, 2001.
27.
OssowskiL, Aguirre-GhisoJA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol12: 613620, 2000.
28.
KjollerL. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol Chem383: 519, 2002.
29.
ReuningU, MagdolenV, HapkeS, SchmittM. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. Biol Chem384: 11191131, 2003.
30.
BehrendtN, PlougM, PatthyL, HouenG, BlasiF, DanoK. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem266: 78427847, 1991.
31.
SideniusN, BlasiF. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin. FEBS Lett470: 4046, 2000.
32.
LiY, LawrenceDA, ZhangL. Sequences within domain II of the urokinase receptor critical for differential ligand recognition. J Biol Chem278: 2992529932, 2003.
33.
WeiY, LukashevM, SimonDI, BodarySC, RosenbergS, DoyleMV, ChapmanHA. Regulation of integrin function by the urokinase receptor. Science273: 15511555, 1996.
34.
DePasqualeJA. Cell matrix adhesions and localization of the vitronectin receptor in MCF-7 human mammary carcinoma cells. Histochem Cell Biol110: 485494, 1998.
35.
LawrenceDA, BerkenpasMB, PalaniappanS, GinsburgD. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem269: 1522315228, 1994.
36.
StefanssonS, PetitclercE, WongMK, McMahonGA, BrooksPC, LawrenceDA. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem276: 81358141, 2001.
37.
NykjrA, ConeseM, ChristensenEI, OlsonD, CremonaO, GliemannJ, BlasiF. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J16: 26102620, 1997.
38.
CzekayRP, KuemmelTA, OrlandoRA, FarquharMG. Direct binding of occupied urokinase receptor (uPAR) to low-density lipoprotein receptor–related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol Biol Cell12: 14671479, 2001.
39.
Murphy-UllrichJE. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state?J Clin Invest107: 785790, 2001.
40.
DanoK, RomerJ, NielsenBS, BjornS, PykeC, RygaardJ, LundLR. Cancer invasion and tissue remodeling–cooperation of protease systems and cell types. APMIS107: 120127, 1999.
